Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Bernstein has turned more optimistic on the Life Science Tools & Diagnostics sector, suggesting the market may be underestimating recovery potential after significant stock declines.
Bernstein analyst Eve Burstein describes the current market as a "mirror image" of early 2024, noting that "the (almost) worst case scenario is already priced in, and yet there is reason to believe that things could go better than expected." The firm points out that stocks have already absorbed approximately 7 percentage points of decline related to academic and government market concerns. According to InvestingPro analysis, Illumina (NASDAQ:ILMN)’s current Fair Value indicates the stock is slightly undervalued, with additional ProTips suggesting strong returns over recent months despite market challenges.
Several potential positive factors could emerge, according to the analysis. These include the possibility that NIH budget cuts may not materialize, pauses on indirect caps could hold, and the impact of economic tensions with China might be mitigated through "in China for China" policies. The firm also notes that new growth economies like India could offset some challenges.
Bernstein observes that the tools sector has been disproportionately punished compared to pharmaceuticals, dropping over 10 percentage points more since election day despite facing similar regulatory risks. The analysis also identifies potential positive regulatory developments, including possible FDA deregulation and AI advancements.
While Bernstein has become more bullish than in 2024, the firm isn’t yet "ready to pound the table" on these stocks due to the lack of clear catalysts. However, it suggests that "another ~2 quarters of solid prints" without further deterioration could reassure investors and improve sector performance. For deeper insights into the sector’s potential, InvestingPro subscribers can access comprehensive research reports covering 1,400+ US stocks, including detailed analysis of key players like Illumina, which maintains a moderate debt level and shows promising earnings forecasts for the year ahead.
In other recent news, Standard BioTools Inc. has announced the sale of its SomaLogic business to Illumina, Inc. for up to $425 million. The transaction includes $350 million in upfront cash and up to $75 million in milestone payments, along with 2% royalties on certain product sales for a decade. This move is expected to simplify Standard BioTools’ operations and help them achieve adjusted EBITDA break-even, with an anticipated cash reserve of at least $550 million post-sale. The deal aligns with Standard BioTools’ strategy of acquiring and commercializing underappreciated assets in lucrative markets. Illumina, on the other hand, aims to enhance its presence in the proteomics market through this acquisition, which is projected to become profitable by 2027. The transaction is subject to regulatory approvals and is expected to close in the first half of 2026. Meanwhile, Canaccord Genuity has raised Illumina’s stock price target to $99, maintaining a Hold rating, following discussions about the company’s new customer-centric strategy. The analysts noted macroeconomic challenges but expressed improved confidence in Illumina’s medium-term execution.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.